Pre-made Lulizumab benchmark antibody ( Single Domain Variable Fragment;L, anti-CD28 therapeutic antibody, Anti-Tp44 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-326
Pre-Made Lulizumab biosimilar, Single Domain Variable Fragment;L, Anti-CD28 Antibody: Anti-Tp44 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lulizumab pegol (INN; development code BMS-931699) is a monoclonal antibody designed for the treatment of autoimmune diseases. This drug was developed by Bristol-Myers Squibb.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Lulizumab biosimilar, Single Domain Variable Fragment;L, Anti-CD28 Antibody: Anti-Tp44 therapeutic antibody|
|Format||Single Domain Variable Fragment;L|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Sjogren's syndrome;Systemic lupus erythematosus;Renal transplant rejection|